araag2/HINT huggingface dataset:
Clinical trial NCT01382147 (phase 3, status: completed)
Conditions: acute myeloid leukemia
ICD codes: C92.A1, C92.A2, C92.61, C92.62, C92.A0, C92.60
Drugs: ara-c, mitoxantrone, daunorubicin, thioguanin
SMILES: OCCNCCNC1=CC=C(NCCNCCO)C2=C1C(=O)C1=C(C(O)=CC=C1O)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with newly diagnosed AML (except acute promyelocytic leukemia) according to
             the WHO classification including patients with secondary AML and AML after preceding
             hematologic disorders

          -  Age 18 years or older

          -  Informed consent. Before any study specific procedure including randomisation is done
             or before study medication is administered, the subject, or legally acceptable
             representative, must have given written informed consent for participation in the
             study.

        Exclusion Criteria:

          -  Acute promyelocytic leukemia (APL)

          -  Previous or concurrent malignancies other than AML

          -  Previous treatment with colony-stimulating factors, interleukins or interferons

          -  Known hypersensitivity to Escherichia coli derived products (e.g. Filgrastim, HUMULIN®
             Insulin, L-Asparaginase, HUMATROPE® Growth Hormone, INTRON A®)

          -  Antibody-based or cell-based immunotherapies

          -  Respiratory insufficiency with pO2 <60 mmHg

          -  Heart failure NYHA III° or IV°

          -  Elevated creatinine >2.0 mg/dl

          -  Elevated bilirubin >2.0 mg/dl

          -  Pregnancy or lactation

          -  Females without adequate contraception

          -  Known HIV and/or hepatitis C infection

          -  Severe neurologic or psychiatric disease

          -  Psychiatric, addictive, or any disorder, which compromises ability to give truly
             informed consent for participation in this study

          -  Concerns for subject's compliance with the protocol procedures

          -  Lack of willingness to record and circulate personal disease-related informations
             defined in the study protocol
Clinical trial NCT01474772 (phase 3, status: completed)
Conditions: diabetic peripheral neuropathy
ICD codes: A18.2, H11.043, H11.053, H18.463, H35.40, H81.393, I73.9
Drugs: pregabalin
SMILES: NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Men or women who are at least 18 years old.

          -  Diagnosis of painful diabetic peripheral neuropathy.

          -  Pain on walking.

        Exclusion Criteria:

          -  Inability to walk 50 feet on a flat surface.

          -  Pain on walking due to conditions other than diabetic peripheral neuropathy.
Clinical trial NCT00275054 (phase 3, status: completed)
Conditions: chronic lymphocytic leukemia
ICD codes: C91.11, C91.12, C91.10
Drugs: fludarabine, cyclophosphamide
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Established diagnosis of B-cell chronic lymphocytic leukemia

               -  First diagnosis within 12 months before inclusion in study

               -  Previously untreated disease

          -  Binet stage A disease (Rai stage 0, I, or II)

        PATIENT CHARACTERISTICS:

          -  Life expectancy > 6 months

          -  ECOG performance status 0-2

          -  Willingness to accept contraception (if randomized to arm I) for the duration of
             therapy and 12 months thereafter

          -  Negative serum pregnancy test

          -  All parameters for risk stratification (lymphocyte doubling time, cytogenetics,
             unmutated IgVH, and serum thymidine kinase level > 10) present

        PRIOR CONCURRENT THERAPY:

          -  No prior chemotherapy, radiotherapy, or antibody treatment

          -  No other concurrent chemotherapy
Clinical trial NCT01516879 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: atorvastatin, ezetimibe
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject has provided informed consent.

          -  Fasting LDL-C ≥ 75 mg/dL and meeting the following LDL-C values on background
             lipid-lowering therapy:

               -  < 100 mg/dL for subjects with diagnosed coronary heart disease (CHD) or CHD risk
                  equivalent

               -  < 130 mg/dL for subjects without diagnosed CHD or CHD risk equivalent

               -  OR on maximal background lipid-lowering therapy defined as atorvastatin 80 mg PO
                  QD and ezetimibe 10 mg PO QD

          -  Fasting triglycerides ≤ 400 mg/dL

        Exclusion Criteria:

          -  New York Heart Association (NYHA) II-IV heart failure, or last known left ventricular
             ejection fraction < 30%

          -  Uncontrolled cardiac arrhythmia

          -  Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI),
             coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization,
             type 1 diabetes, newly diagnosed or poorly controlled type 2 diabetes

          -  Uncontrolled hypertension
Clinical trial NCT00203138 (phase 3, status: completed)
Conditions: parkinson's disease
ICD codes: G20
Drugs: rasagiline mesylate
SMILES: C#CCN[C@@H]1CCC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

        • Patients who completed evaluations of week 52 of the TVP 1012/232 protocol, where
        continued rasagiline therapy is warranted, in the opinion of the principal investigator

        Exclusion Criteria:

        • Patients having suffered adverse effects that were probably drug-related in the
        TVP-1012/232 study
Clinical trial NCT00252720 (phase 3, status: completed)
Conditions: type 1 diabetes
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: candesartan
SMILES: CCOC1=NC2=C(N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NN=NN1)C(=CC=C2)C(=O)OC(C)OC(=O)OC1CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18 - 55 years with type 1 diabetes diagnosed before age of 36
             years and in need for continuous insulin treatment within 1 year of diagnosis of
             diabetes are included.

          -  Duration of diabetes for > 1 year and < 20 years with stable diabetic therapy within
             last 6 months.

          -  Patients with untreated resting mean sitting SBP < 130 mmHg, mean sitting DBP < 85
             mmHg and with retinal photograph grading level > 20/10 up to < 47/47 (on ETDRS
             severity scale).

        Exclusion Criteria:

          -  Patients with the following conditions are excluded from participation on the study:

          -  Cataract or media opacity of a degree which precludes taking gradable retinal
             photographs

          -  Angle closure glaucoma, which precludes pharmacological dilatation of the pupil

          -  History or presence of proliferative retinopathy

          -  History or presence of clinical significant macular oedema (CSME)

          -  History or evidence of photocoagulation of the retina

          -  Other retinal conditions which may mask assessment, eg, retinal vein occlusion

          -  Positive micral dipstick test

          -  Presence of secondary diabetes

          -  Pregnant or lactating women or women of child bearing potential not practicing an
             adequate method of contraception

          -  Need of treatment with ACE-inhibitor

          -  Haemodynamically significant aortic or mitral valve stenosis

          -  Known renal artery stenosis or kidney transplantation

          -  Hypersensitivity to study drug

          -  Severe concomitant disease which may interfere with the assessment of the patient, eg,
             malignancy, as judged by the investigator
Clinical trial NCT00627952 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: amlodipine 10 mg, manidipine 20 mg, amlodipine 5 mg + delapril 30 mg, manidipine 10 mg + delapril 30 mg
SMILES: CCOC(=O)C1=C(COCCN)NC(C)=C(C1C1=CC=CC=C1Cl)C(=O)OC, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)(C)CN(C)CCC(C1=CC=CC=C1)C1=CC=CC=C1, COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  male or female patients aged 18 years or older

          -  mild to moderate hypertension (systolic blood pressure > 139 mmHg or diastolic blood
             pressure > 89 mmHg)

        Exclusion Criteria:

          -  secondary form of arterial hypertension

          -  severe hypertension (systolic blood pressure > 179 mmHg or diastolic blood pressure >
             109 mmHg)

          -  pregnant or lactating women
Clinical trial NCT01072448 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: indacaterol 75 μg, placebo to indacaterol
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1, CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as
             classified by the Global Initiative for Chronic Obstructive Lung Disease [GOLD]
             Guidelines, 2008) and:

               -  Smoking history of at least 10 pack-years

               -  Post-bronchodilator forced expiratory volume in 1 second (FEV1) < 80% and ≥ 30%
                  of the predicted normal value

               -  Post-bronchodilator FEV1/FVC (forced vital capacity) < 70%

        Exclusion criteria:

          -  Patients who have had a COPD exacerbation requiring systemic corticosteroids and/or
             antibiotics and/or hospitalization in the 6 weeks prior to screening

          -  Patients who have had a respiratory tract infection within 6 weeks prior to screening

          -  Patients with concomitant pulmonary disease

          -  Patients with a history of asthma

          -  Patients with diabetes Type I or uncontrolled diabetes Type II

          -  Any patient with lung cancer or a history of lung cancer

          -  Patients with a history of certain cardiovascular co-morbid conditions Other
             protocol-defined inclusion/exclusion criteria applied to the study.
Clinical trial NCT00120796 (phase 3, status: terminated)
Conditions: hepatitis b
ICD codes: B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, B16.1
Drugs: lamivudine
SMILES: CC1=CN([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)C(=O)NC1=O
Reason stopped: 
    poor patient recrutment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent

          -  Liver biopsy acceptation

          -  B hepatitis grade over or equal to F2 Metavir score

          -  DNA HBV greater than 100000 copies/mL (or 10000 copies/mL if Ag Hbe negative)

          -  ALAT greater than 1.3 times the upper normal limit

        Exclusion Criteria:

          -  HCV, HDV and HIV positive

          -  Pregnancy

          -  Decompensated liver cirrhosis

          -  Pretreated patient
Clinical trial NCT00376259 (phase 3, status: terminated)
Conditions: hepatitis b
ICD codes: B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, B16.1
Drugs: telbivudine, adefovir dipivoxil
SMILES: CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C
Reason stopped: 
    the study was not completed as planned and was terminated early with agreement from the
    european medicines agency (emea)
  
Eligibility criteria:

        Inclusion Criteria:

          -  Documented compensated chronic hepatitis B defined by a clinical history compatible
             with chronic hepatitis B.

          -  Previous or current lamivudine treatment

          -  HBV DNA > 6 log10 copies/mL

          -  Evidence of viral breakthrough

        Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Patient is pregnant or breastfeeding.

          -  Patient is co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV.

          -  Patient has received any anti-HBV treatment for HBV infection other than lamivudine in
             the 12 months before Screening for this study.

        Other protocol-defined exclusion criteria may apply.
Clinical trial NCT01018511 (phase 3, status: completed)
Conditions: benign prostatic hyperplasia, lower urinary tract symptoms
ICD codes: N40.0, N40.1, N40.2, N40.3, N40.0, N40.1
Drugs: placebo tamsulosin hydrochloride ocas 0.4 mg, placebo fdc tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg, placebo fdc tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg, tamsulosin hydrochloride ocas 0.4 mg, tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg), tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O, CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O, CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC(=C(OC)C=C1)S(N)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Voiding and storage symptoms diagnosed as LUTS associated with BPH for ≥ 3 months

          -  A total International Prostate Symptom Score (IPSS) of ≥13

          -  A maximum urinary flow rate of ≥4.0 mL/s and ≤12.0 mL/s, with voided volume of ≥120 mL
             during free flow

          -  A micturition frequency of ≥8 and at least 2 episodes of urgency with Patient
             Perception of the Intensity of Urgency Scale grade 3 or 4 per day on average on the 3
             day micturition diary (at randomization)

        Exclusion Criteria:

          -  Any significant Post Void Residual volume (>150 mL)

          -  A prostate with estimated weight ≥75 ml as assessed by transvesical or transrectal
             ultrasound

          -  Evidence of a symptomatic urinary tract infection
Clinical trial NCT00143390 (phase 3, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: exemestane, anastrozole
SMILES: CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N
Eligibility criteria:

        Inclusion Criteria:

          -  Have histologically or cytologically confirmed breast cancer at original diagnosis. At
             study entry, the patient must have metastatic progressive or locally recurrent
             inoperable breast cancer.

        Exclusion Criteria:

          -  Having received any hormonal therapy (e.g., Tamoxifen, LHRH-agonists) ovariectomy or
             any chemotherapy for advanced/recurrent breast cancer
Clinical trial NCT01018173 (phase 3, status: completed)
Conditions: diabetes mellitus type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, taspoglutide
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC[C@H](C)[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC1=CNC=N1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >18 years of age

          -  diabetes mellitus type 2

          -  HbA1c >/=6.5% and </=10% at screening

          -  BMI >/=23kg/m2

          -  cardiovascular disease with onset >/=1 month prior to screening

        Exclusion Criteria:

          -  diagnosis or history of type 1 diabetes or secondary forms of diabetes

          -  acute metabolic diabetic complications within past 6 months

          -  severe hypoglycemia </=1 month prior to screening

          -  clinically significant gastrointestinal disease

          -  history of chronic or acute pancreatitis

          -  current New York Heart Association (NYHA) class IV heart failure or
             post-transplantation cardiomyopathy

          -  severely impaired renal function
Clinical trial NCT00439725 (phase 3, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: rivaroxaban (xarelto, bay59-7939), placebo
SMILES: ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with confirmed symptomatic PE or DVT who have been treated for 6 or 12 months
             with VKA or rivaroxaban

        Exclusion Criteria:

          -  Legal lower age limitations (country specific)

          -  Indication for VKA other than DVT and/or PE

          -  Patients in whom anticoagulant treatment for their index PE or DVT should be continued

          -  Childbearing potential without proper contraceptive measures, pregnancy or breast
             feeding. Proper contraceptive measures are defined as a method of contraception with a
             failure rate < 1 % during the course of the study (including the observational
             period). These methods of contraception according to the note for guidance on
             non-clinical safety studies for the conduct of human trials for pharmaceuticals (CPMP
             [Committee for Proprietary Medicinal Products]/ICH [International Conference on
             Harmonization]/286/95, modification) include consistent and correct use of hormone
             containing implants and injectables, combined oral contraceptives, hormone containing
             intrauterine devices, surgical sterilization, sexual abstinence and vasectomy
Clinical trial NCT00422383 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: rituximab [mabthera/rituxan], rituximab [mabthera/rituxan], rituximab [mabthera/rituxan]
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients >=18 years of age;

          -  RA for >=6 months;

          -  receiving outpatient treatment;

          -  inadequate response to methotrexate, having received and tolerated it for >=12 weeks,
             with a stable dose for >=4 weeks.

        Exclusion Criteria:

          -  rheumatic autoimmune disease other than RA, or significant systemic involvement
             secondary to RA;

          -  inflammatory joint disease other than RA, or other systemic autoimmune disorder;

          -  diagnosis of juvenile arthritis, or RA before the age of 16;

          -  previous treatment with >1 biologic agent, any cell-depleting therapies, or concurrent
             treatment with any biologic agent or DMARD other than methotrexate.
Clinical trial NCT00412100 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: oxycodone naloxone prolonged release tablets (oxn)
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subjects at least 18 years or older with moderate to severe pain that
             requires around the clock opioid therapy. Subjects must report constipation caused or
             aggravated by opioids.

        Exclusion Criteria:

          -  Females who are pregnant or lactating.

          -  Subjects with evidence of any clinically unstable disease or subjects with evidence of
             impaired liver/kidney function upon entry into the study.

          -  Subjects with evidence of significant structural abnormalities of the gastrointestinal
             tract.
Clinical trial NCT00332306 (phase 3, status: unknown status)
Conditions: tuberculosis, human immunodeficiency virus infections
ICD codes: A18.39, P37.0, Z22.7, A15.0, A15.7, A15.8, A15.9, Z21
Drugs: didanosine, lamivudine, efavirenz, didanosine, lamivudine, nevirapine
SMILES: OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O, OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O
Eligibility criteria:

        Inclusion Criteria:

          1. Age > 18 years

          2. a) Newly diagnosed sputum smear positive tuberculosis (at least 1 out of 6 sputum
             specimen should be positive by smear) b)Miliary tuberculosis, mediastinal/hilar
             lymphadenopathy, diagnosed by chest radiography or CT scan (irrespective of sputum
             smear status).

             c)TB lymphadenitis with histopathological/bacteriological evidence of TB d)Pleural
             effusion with biochemical/cytological/bacteriological evidence of TB

          3. HIV-1 positivity (on 2 different rapid tests on the same blood sample)

          4. CD4 cell counts less than 250 cells/mm3

          5. Likely to remain in the same area for at least two years after start of treatment.

          6. Willingness to stay in the hospital for 2 weeks during initiation of ART, and attend
             the clinic thrice weekly for the entire period of the study (up to 2 years).

          7. Willingness for home visits, and to attend for investigations, supervised treatment
             and follow-up as required.

          8. Within the area of intake (25 kms from any of the TRC subcentres).

          9. Willingness to use contraception during trial period.

        Exclusion Criteria:

          1. Resides outside area of intake.

          2. Pregnancy and lactation.

          3. Patients with major psychiatric illnesses and severe depression

          4. Major complications of HIV disease like encephalopathy, renal (Serum creatinine level
             > 1.2 mgs/dl) or hepatic disease (Serum bilirubin > 2.0 times upper limit of normal,
             Serum transaminases > 2.5 times upper limit of normal), serum amylase > 2 times upper
             limit of normal with serum lipase > 1.5 times upper limit of normal.

          5. Serious cardiac disease (CCF, IHD), uncontrolled diabetes mellitus, cancer, moribund
             state

          6. Previous antituberculosis treatment for more than 1 month.

          7. Previous antiretroviral treatment for more than 1 month

          8. Patients with CD4 cell count >250 cells/mm3.

          9. HIV-2 infection alone or in combination with HIV-1.

         10. Patients currently using alcohol, IV drugs & other substance abuse.

         11. Unwilling to use contraception & avoid pregnancy.

         12. Unwilling to HIV/TB screening and participation in trial.